english.prescrire.org > Prescrire International > N°121 - November 2011

n°121

November 2011

Issue Contents
Editorial

Free  DES: an ongoing disaster

p.256
Important lessons are still being overlooked

New Products


Quetiapine (New Drug)

p.257-261
A me-too neuroleptic; no panacea

Fondaparinux and isolated superficial-vein thrombosis (New Indication)

p.262
Of little interest

Omalizumab 75 mg (New Dosage)

p.262
Whatever the dosage, the drug should be avoided in severe persistent asthma

Free  Onsenal°: marketing authorisation withdrawn in the European Union (Marketing Withdrawal)

p.263
Company failed to supply required data

Free  INN common-stem: -conazole

p.263

Adverse Effects


Psychological consequences of DES exposure in utero

p.264-266
Long-term studies are needed

Prenatal DES exposure: long-term somatic effects

p.265

Exenatide and sitagliptin: pancreatitis and pancreatic cancer

p.267
Harms on the rise

Dutasteride: high-grade prostate cancer

p.267
Risky in prostate cancer prevention

Tadalafil: visual and auditory disorders

p.267
Inform patients of these risks

Reviews


Analgesia for terminally ill adult patients

p.268-273
Preserve quality of life

Simple cystitis

p.273
Symptoms persist longer without antibiotics

Outlook


Analysing an adverse event in primary care: a multidisciplinary, collaborative process

p.274-278
Promoting a culture of safety

Free  European Medicines Agency: reliance on placebo studies is unacceptable

p.278
New drugs must be compared to established treatments

Free  The Mediator° scandal in France: key dates, key issues

p.280

Masthead


Free  Masthead

p.254

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe